• Explore /
  • Poster
  • / TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).

TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).

Abstract Poster

Authors

null

Wassim Abida

Memorial Sloan Kettering Cancer Center, New York, NY

Wassim Abida , Alan Haruo Bryce , Arjun Vasant Balar , Gurkamal S. Chatta , Nancy Ann Dawson , Elizabeth A. Guancial , Arif Hussain , Gautam Gopalji Jha , David Uri Lipsitz , Akash Patnaik , Daniel Peter Petrylak , Charles J. Ryan , Thomas S. Stanton , Nicholas J. Vogelzang , Jingsong Zhang , Andrew Simmons , Jowell Go , Tony Golsorkhi , Simon Chowdhury , Howard I. Scher

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02952534

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr TPS388)

DOI

10.1200/JCO.2018.36.6_suppl.TPS388

Abstract #

TPS388

Poster Bd #

P6

Abstract Disclosures

Similar Posters

First Author: Charles J. Ryan

First Author: Charles J. Ryan

First Author: Qiuxiang Ou

First Author: Benedito A. Carneiro